Abstract
Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.
Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.
Current Pharmacogenomics and Personalized Medicine
Title:Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors
Volume: 16 Issue: 2
Author(s): Wei-Hua Shao, Lei-Yun Wang and Ji-Ye Yin*
Affiliation:
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008,China
Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.
Abstract: Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.
Export Options
About this article
Cite this article as:
Shao Wei-Hua , Wang Lei-Yun and Yin Ji-Ye *, Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors, Current Pharmacogenomics and Personalized Medicine 2018; 16 (2) . https://dx.doi.org/10.2174/1875692116666180821152601
DOI https://dx.doi.org/10.2174/1875692116666180821152601 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Current Medicinal Chemistry Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry The Cytoskeleton as a Therapeutic Target in Childhood Acute Leukemia:Obstacles and Opportunities
Current Drug Targets Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy
Current Drug Targets miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Osteoporosis Requires Bone-Specific Statins
Current Pharmaceutical Design <i>Qiliqiangxin</i> Prescription Promotes Angiogenesis of Hypoxic Primary Rat Cardiac Microvascular Endothelial Cells via Regulating miR-21 Signaling
Current Pharmaceutical Design H+-myo-Inositol Transporter SLC2A13 as a Potential Marker for Cancer Stem Cells in an Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Recent Clinical Experience with Oncolytic Viruses
Current Pharmaceutical Biotechnology Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy
Current Pharmaceutical Design Inhibition of Lysozyme by Taurine Dibromamine
Protein & Peptide Letters Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer
Current Molecular Medicine Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice
Letters in Drug Design & Discovery Human Carbonyl Reductases
Current Drug Metabolism Squalamine as an Example of a New Potent Antimicrobial Agents Class: A Critical Review
Current Medicinal Chemistry